BioSyent

BioSyent Net Tangible Assets

The Net Tangible Assets of BioSyent (RX.V) as of Oct 27, 2026 is 41.47 M CAD. In the previous year, Net Tangible Assets was 29.96 M CAD — a change of 38.40% (higher).

Net Tangible Assets

41.47 MCAD

YoY

38.40%

Last updated:

Net Tangible Assets of BioSyent is 2025 41.47 M CAD. Net Tangible Assets of BioSyent was 2024 29.96 M CAD. It decreases by 38.40% higher compared to the previous year.

The BioSyent Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2018
25.66 M CAD
Jan 1, 2019
24.77 M CAD
Jan 1, 2020
25.79 M CAD
Jan 1, 2021
30.68 M CAD
Jan 1, 2022
32.16 M CAD
Jan 1, 2023
33.61 M CAD
Jan 1, 2024
29.96 M CAD
Jan 1, 2025
41.47 M CAD
The BioSyent Net Tangible Assets history
YEARNet Tangible AssetsYoY
41.47 MCAD+38.40%
29.96 MCAD-10.85%
33.61 MCAD+4.49%
32.16 MCAD+4.83%
30.68 MCAD+18.97%
25.79 MCAD+4.11%
24.77 MCAD-3.48%
25.66 MCAD+24.92%
20.54 MCAD+32.97%
15.45 MCAD+39.54%
11.07 MCAD+36.80%
8.09 MCAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioSyent stock

Net Tangible Assets of BioSyent is 41.47 M CAD in 2025.

Net Tangible Assets of BioSyent changed from 29.96 M CAD to 41.47 M CAD, representing a 38.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets BioSyent since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's BioSyent historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioSyent

All Key Metrics — BioSyent